Repare Therapeutics (RPTX) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Repare Therapeutics is set to announce its Q2 2025 earnings results on Tuesday, August 5th, with analysts predicting an earnings loss of ($0.56) per share and revenue of $2.50 million.
• The company’s stock recently traded at $1.55, with a market capitalization of $66.48 million and a 12-month trading range from $0.89 to $4.10.
• Acadian Asset Management LLC has raised its stake in Repare Therapeutics by 35.6%, now owning approximately 1.49% of the company, reflecting strong institutional interest as 85.09% of the stock is owned by institutional investors.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 5th. Analysts expect Repare Therapeutics to post earnings of ($0.56) per share and revenue of $2.50 million for the quarter.

Repare Therapeutics Price Performance

NASDAQ RPTX traded down $0.01 during mid-day trading on Friday, hitting $1.51. The company's stock had a trading volume of 68,025 shares, compared to its average volume of 328,239. Repare Therapeutics has a 52-week low of $0.89 and a 52-week high of $4.07. The stock's fifty day simple moving average is $1.46 and its two-hundred day simple moving average is $1.29. The firm has a market capitalization of $64.55 million, a P/E ratio of -0.50 and a beta of 0.84.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Repare Therapeutics stock. Acadian Asset Management LLC boosted its holdings in Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) by 35.6% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 640,332 shares of the company's stock after buying an additional 168,230 shares during the period. Acadian Asset Management LLC owned approximately 1.49% of Repare Therapeutics worth $624,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 85.09% of the company's stock.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.